GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TetraLogic Pharmaceuticals Corp (OTCPK:TLOG) » Definitions » Tangible Book per Share

TLOG (TetraLogic Pharmaceuticals) Tangible Book per Share : $-2.72 (As of Sep. 2016)


View and export this data going back to 2013. Start your Free Trial

What is TetraLogic Pharmaceuticals Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. TetraLogic Pharmaceuticals's tangible book value per share for the quarter that ended in Sep. 2016 was $-2.72.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


TetraLogic Pharmaceuticals Tangible Book per Share Historical Data

The historical data trend for TetraLogic Pharmaceuticals's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TetraLogic Pharmaceuticals Tangible Book per Share Chart

TetraLogic Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
Tangible Book per Share
-41.15 -137.99 2.28 -1.12 -1.92

TetraLogic Pharmaceuticals Quarterly Data
Dec11 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.08 -1.92 -2.33 -2.58 -2.72

Competitive Comparison of TetraLogic Pharmaceuticals's Tangible Book per Share

For the Biotechnology subindustry, TetraLogic Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TetraLogic Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TetraLogic Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where TetraLogic Pharmaceuticals's Price-to-Tangible-Book falls into.



TetraLogic Pharmaceuticals Tangible Book per Share Calculation

TetraLogic Pharmaceuticals's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2015 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(-5.941-0-41.576)/24.7691
=-1.92

TetraLogic Pharmaceuticals's Tangible Book Value Per Share for the quarter that ended in Sep. 2016 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(-30.938-0-36.407)/24.7691
=-2.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


TetraLogic Pharmaceuticals  (OTCPK:TLOG) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


TetraLogic Pharmaceuticals Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of TetraLogic Pharmaceuticals's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


TetraLogic Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
343 Phoenixville Pike, Malvern, PA, USA, 19355
TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.
Executives
Hudson Bay Capital Management Lp other: See Remarks 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Lazard Asset Management Llc other: See Remarks 30 ROCKEFELLER PLZ, 56TH FL., NEW YORK NY 10112
Nomura Holdings Inc other: See Remarks 1-13-1 NIHONBASHI, CHUO-KU, TOKYO M0 103-8645
Whitebox Multi-strategy Partners Lp other: See Remarks 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Pandora Select Partners, L.p. other: See Remarks 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox General Partner Llc other: See Remarks 3033 EXCELSIOR BLVD., SUITE 300, MINNEAPOLIS MN 55416
Highbridge Capital Management Llc other: See Remarks 277 PARK AVE, 23RD FLOOR, NEW YORK NY 10172
Sander Gerber other: See Remarks C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Whitebox Concentrated Convertible Arbitrage Partners, L.p. other: See Remarks 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox Advisors Llc other: See Remarks 3033 EXCELSIOR BLVD., SUITE 500, MINNEAPOLIS MN 55416
Patrick Hutchison officer: CFO & Treasurer C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
Clarus Ventures Ii, Llc 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Lifesciences Ii, L.p. 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Ventures Ii Gp, L.p. 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Nicholas Simon 10 percent owner 101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142

TetraLogic Pharmaceuticals Headlines

No Headlines